News Focus
News Focus
Followers 33
Posts 3040
Boards Moderated 0
Alias Born 01/26/2011

Re: BarrellofHay post# 397562

Thursday, 01/12/2023 11:55:22 AM

Thursday, January 12, 2023 11:55:22 AM

Post# of 517607
12x - where you at? Interested to hear his/her thoughts on the statement below (along with the thoughts of the other hardcore biotech geeks here)...

Here are some facts:
lecanemab primary endpoint was CDR-SB and data here with time course (to 18 months): https://www.nejm.org/doi/full/10.1056/NEJMoa2212948
Anavex-273 data with time course looks better at week 48 than at week 72 for lecanemab
The patients will be evaluated for Anavex-273 out to 96 weeks.
In other words apples to apples data comparison to lecanemab shows a better outcome for 273 using the primary endpoint that the FDA used to accept the drug for approval. I think this is pretty good and new

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News